Skip to content

A Study is to Evaluate a Regimen on Gingivitis Using Traditional and Novel Assessment Methods

A SIX WEEK CLINICAL STUDY TO EVALUATE THE EFFECT OF A REGIMEN ON GINGIVITIS

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07211061
Enrollment
69
Registered
2025-10-07
Start date
2011-09-21
Completion date
2011-11-10
Last updated
2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis

Brief summary

Subjects who have shown evidence of gingivitis and plaque will be enrolled in this study. Each subject will be randomly assigned to one of two treatment products. The regimen group will be asked to brush 2x a day in using a power brush (2 minutes of brushing), followed by using 20 ml of mouth rinse for 30 seconds for 6 weeks. The negative control group will be asked to brush 2x a day using a manual toothbrush in their customary manner for 6 weeks. Oral Soft Tissue (OST) assessments, gingivitis and plaque measurements will be taken at 4 time-points: Baseline (BL); Week 1; Week 3; and Week 6.

Interventions

brush 2x a day in using a power brush (2 minutes of brushing)

brush in their customary manner

brush using a electric brush (2 minutes of brushing)

use 20 ml of mouth rinse for 30 seconds

DEVICEmanual toothbrush

brush in their customary manner

Sponsors

Procter and Gamble
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Provide written informed consent to participate in the study; * Be 18 years of age or older; * Agree not to participate in any other oral/dental product studies during the course of this study; * Agree to delay any elective dentistry (including dental prophylaxis) until the study has been completed; * Agree to refrain from any form of non-specified oral hygiene during the treatment periods, including but not limited to the use of products such as floss or whitening products; * Have a Baseline MGI score of at least 1.75 but not greater than 2.3; * Have at least 20 bleeding sites (sites with a score of 1 or 2 on the GBI index); * Agree to return for all scheduled visits and follow study procedures; * Be in good general health, as determined by the Investigator/designee based on a review of the health history/update for participation in the study.

Exclusion criteria

* Have had a dental prophylaxis within 2 weeks of Baseline visit; * Have taken antibiotics or used anti-gingivitis / anti-bacterial oral care products such as chlorhexidine or Listerine within 2 weeks of plaque sampling visits; * Have rampant caries, open or untreated caries, severe gingivitis, or advanced periodontitis requiring prompt treatment; or, * Need an antibiotic prophylaxis prior to dental visits, * Present with any disease or condition(s) that could be expected to interfere with examination procedures or the subject's safe completion of the study, * Are pregnant (Self-reported) or lactating.

Design outcomes

Primary

MeasureTime frameDescription
Bleeding (GBI)Week 1, Week 3, and Week 6Gingival Bleeding Index- evaluation of bleeding from gingival tissue, score from 0-2

Secondary

MeasureTime frameDescription
Inflammation (MGI)Week 1, Week 3, and Week 6Modified Gingival Index- evaluation of the level of gingival tissue inflammation, scores from 0-4

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026